Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Panel To Take Up Lutonix DCB Catheter For Lower-Leg Use Next Month

Executive Summary

If approved, the device will be the first drug-coated balloon indicated specifically for use in arteries below the knee.

You may also be interested in...



FDA Panel Votes No On BD's Balloon For Below The Knee

Shifting trial design and missing data, plus little evidence of benefit, worked against the paclitaxel-coated balloon, panelists and US FDA speakers said.

MedAlliance Launches PRISTINE Study Of SELUTION SLR Drug-Eluting Peripheral Balloon

SELUTION SLR is the first drug-eluting balloon accepted by the FDA as part of its breakthrough program, according to the company.

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel